Julián Alejandro Rivillas/LinkedIn
Oct 24, 2025, 12:08
Julián Alejandro Rivillas Compares Tenecteplase to Low-dose Alteplase: TRACE-5 Interim Phase II Results
Julián Alejandro Rivillas, Stroke Fellow at University of Montreal Hospital Center, shared on LinkedIn:
”DAY 1: TRACE-5: Tenecteplase improved 90-day functional outcomes and early reperfusion compared with low-dose alteplase, with no safety difference — interim phase II results.”
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Aug 21, 2026, 12:57David McIntosh: Why Do Blood Supplies Still Fall Short?
-
Aug 21, 2026, 12:48Joshua Penrod: 35 Years of Progress in Plasma Safety
-
Aug 21, 2026, 12:42Moustafa Abdou: Diagnosis and Management of Pyruvate Kinase Deficiency
-
Aug 21, 2026, 12:38Luluva Ghadiyali: Modern Approaches to Aplastic Anemia
-
Aug 21, 2026, 12:34Kellie Machlus: Animal Models Driving Progress in Thrombosis Research
-
Aug 21, 2026, 12:08Amy Allen Whitfield: Helping to Proceed Bleeding Disorders Care
-
Aug 21, 2026, 11:53Jan Terje Andersen: Harnessing Placental Biology for Therapeutic Engineering
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029